Dana Brantley-Sieders Selected Research

Dana Brantley-Sieders Research Topics

9	Neoplasms (Cancer) 04/2021 - 12/2003
5	Breast Neoplasms (Breast Cancer) 04/2021 - 01/2012
3	Neoplasm Metastasis (Metastasis) 04/2021 - 12/2003
2	Triple Negative Breast Neoplasms 06/2017 - 01/2017
1	Necrosis 04/2015
1	Carcinoma (Carcinomatosis) 04/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 05/2014
1	Lung Neoplasms (Lung Cancer) 05/2014
1	Vascular Remodeling 04/2006
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 04/2006
1	Retinal Neovascularization 04/2006
1	Melanoma (Melanoma, Malignant) 01/2004
1	Neuroblastoma 01/2004
1	Colonic Neoplasms (Colon Cancer) 01/2004
1	Circulating Neoplastic Cells 12/2003

4	Phosphotransferases (Kinase)IBA 06/2017 - 01/2004
3	EphA2 ReceptorIBA 04/2021 - 04/2006
2	Mechanistic Target of Rapamycin Complex 2IBA 06/2017 - 01/2016
2	Phenobarbital (Luminal)FDA Link 06/2017 - 04/2015
2	Small Interfering RNA (siRNA)IBA 01/2017 - 04/2015
2	Tyrosine (L-Tyrosine)FDA Link 04/2006 - 01/2004
2	LigandsIBA 04/2006 - 01/2004
2	EphrinsIBA 04/2006 - 01/2004
2	EphA1 Receptor (Eph Receptor)IBA 04/2006 - 01/2004
1	Interleukin-6 (Interleukin 6)IBA 04/2021
1	A-factor (Streptomyces)IBA 06/2017
1	human ERBB2 proteinIBA 06/2017
1	rho Guanine Nucleotide Dissociation Inhibitor betaIBA 06/2017
1	AlbuminsIBA 01/2017
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2016
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 04/2015
1	Cell-Penetrating PeptidesIBA 04/2015
1	SuspensionsIBA 05/2014
1	pyrazolanthroneIBA 05/2014
1	IgA receptor (protein B)IBA 01/2012
1	Messenger RNA (mRNA)IBA 01/2012
1	Proteins (Proteins, Gene)FDA Link 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2006
1	Retinaldehyde (Retinal)IBA 04/2006
1	Eph Family Receptors (Eph Receptors)IBA 01/2004
1	Pharmaceutical PreparationsIBA 01/2004
1	VimentinIBA 12/2003
1	Transforming Growth Factor beta (TGF-beta)IBA 12/2003
1	Mitogen-Activated Protein KinasesIBA 12/2003
1	Transforming Growth Factor beta1 (TGF beta 1)IBA 12/2003

3	Therapeutics 04/2021 - 01/2017